Buy Jubilant Life Science Ltd For Target Rs.922.00 - India Nivesh Sec

Jubilant Pharma reported numbers which were below our estimates o EBITDA & Adj PAT level while revenue was exactly in‐line with our estimates. The miss on Adj PAT was mainly due to onetime financing charge of Rs 270 mn. Adjusting for this charge the miss was still 10% lower than our expectation.

Pharma business continued momentum & grew by ~15% y‐y v/s our estimate of 10%

18/02/2017 12:04:16 PM | Posted in Broking Firm Views - Long Term Report read full news
Accumulate Glenmark Pharma Ltd For Target Rs.1,013 - Emkay

Zetia to keep earnings buoyant,Maintain ACCUMULATE

* Higher than expected gZetia numbers in Q3 portend much stronger numbers in Q4FY17. However uncertainties over base business performance continue to linger.

*Given strong gZetia cash flows, the extent of consequential debt reduction over the next few quarters is to be closely monitored. We e

18/02/2017 11:46:03 AM | Posted in Broking Firm Views - Long Term Report read full news
Zydus gets USFDA final nod for anti-fungal tablet

Pharma major Cadila Healthcare Ltd on Friday said that Zydus Cadila has received final approval from the US health regulator to market Fluconazole tablets USP and Clobetasol Propionate spray.

“Zydus Cadila has received the final approval from the USFDA to market Fluconazole tables USP in strengths of 50 mg, 100 mg, 150 mg and 200 mg and Clobetasol Propionate spray, 0.05 per cent

Accumulate Alkem Laboratories Ltd For Target Rs.1,996.00 - Angel

Alkem Laboratories

Domestic business remains strong, US business shows strong growth:

Alkem reported revenue grew of 15% yoy in 3QFY17. Domestic revenue grew by 16.8% yoy to `1,030cr while exports grew by 18.7% to `432cr. US revenue grew by 30% yoy to `339cr. Other exports de-grew by 9.8% yoy as company contin

17/02/2017 2:32:05 PM | Posted in Broking Firm Views - Long Term Report read full news
USFDA accepts Biocon`s Biologics License Application

Biocon Ltd. has said that the U.S. Food and Drug Administration (FDA) has accepted Mylan's Biologics License Application (BLA) for MYL-1401H, a proposed biosimilar to Neulasta® (pegfilgrastim), for filing through the 351(k) pathway. The proposed biosimilar to Neulasta is used to reduce the duration of neutropenia (low count of neutrophils, a type of white blood cells) and the incidence

We maintain our NEUTRAL rating on Cadila Healthcare Ltd By Ms. Sarabjit Kour Nangra - Angel

Below is the views on  Cadila Healthcare Ltd  By Ms. Sarabjit Kour Nangra (VP Research- Pharma, Angel Broking Pvt Ltd)

“Cadila Healthcare did not got any 483’s issued in favour of its Moriaya plant. This marks an important relief for the company, Moriaya plant is a significant contributor to the overall sales of the company and has around 74

USFDA inspects Cadila Healthcare`s Moraiya facility

Drug firm Cadila Healthcare today said the US health regulator has inspected the company's Moraiya plant and found it meeting the manufacturing norms. "United States Food and Drug Administration (USFDA) inspected company's Moraiya facility from February 6, 2017 to February 15, 2017.

At the end of the inspection no observation (483) is issued," Cadila Healthcare said

Hold Dr. Reddy`s Laboratories Ltd For Target Rs.3,100.00 - Reliance Sec

Dr. Reddy’s Laboratories

Dr. Reddy’s Laboratories (DRRD) has topped our estimates in 3QFY17. EBITDA margin strongly improved by 5.9% QoQ led by a) better product-mix, b) seasonality in CIS, c) cost control measures, d) higher realization from biosimilar business, and e) favourable currency movement in Emerging Markets (EMs). This is despite

16/02/2017 3:12:10 PM | Posted in Broking Firm Views - Long Term Report read full news
Buy Granules India Ltd For Target Rs.152.00 - Emkay

Granules India

Result highlights

*Re-inspection of Gagillapur by Portugal regulator Inframed shortly likely to limit any revenue loss from stoppage of supplies to Europe

* Capacity constraints which have dragged growth likely to be resolved with new API capacities expected to come on stream by mid FY

16/02/2017 2:43:29 PM | Posted in Broking Firm Views - Long Term Report read full news
Dr. Reddy`s Lab hits 52-week low on patent infringement

Shares of Dr Reddys Laboratories tanked nearly 4 per cent on the Bombay Stock Exchange after the company said that United States District Court of New Jersey issued its opinion regarding Helsinn Healthcare patent infringement claims against the company’s proposed Palonosetron product.

Weighed down by the development, shares of drug maker declined as much as 3.66 per cent and tou

Sun Pharma dips nearly 4% post Q3

Shares of Sun Pharmaceuticals Industries tanked nearly 4 per cent on the Bombay Stock Exchange after the company reported 4.72 per cent decline in its consolidated net profit to Rs 1,471.82 crore for the third quarter ended December 31, 2016, from Rs 1,544.85 crore in the year ago quarter.

Weighed down by Q3 earnings, shares of company declined as much as 3.77 per cent to hit an intra

Pharma pricing regulator cuts stent prices by up to 85%

 In a major measure of relief to cardiac patients in India, the government on Tuesday fixed the ceiling price of coronary stents which are used to open up blocked arteries.

The National Pharmaceutical Pricing Authority, in a notification, put a ceiling price on drug eluting stents (DES) and bioresorbable stents at Rs 29,600, and that of bare metal stents at Rs 7,260, effective fr

India PharmaScope - Convalescing post-demonetisation - RCML

Growth in the Indian Pharmaceutical Market (IPM) recovered to 10.1% YoY in Jan’17 from 7.2% in Dec’16, driven by a volume uptick as demonetisation headwinds receded. Despite improved pricing, NLEM revenues fell 5.5% YoY (-9% in Dec’16) as volumes dropped. While the FDC market remains in pain (-34%), the non-NLEM and non-FDC segments improved. Therapy-wise, antidiabetic drug sa

14/02/2017 5:32:47 PM | Posted in Broking Firm Views - Sector Report read full news
Sun Pharma's profits drop as U.S. sales hit by pricing, supply issues

MUMBAI  - Sun Pharmaceutical Industries, India's largest drugmaker, reported its first fall in quarterly profits in a year on Tuesday, as pricing issues and supply constraints affected sales in the United States, its largest market.

Sun's U.S. business faces increasing uncertainty as it struggles to fix quality control problems found by regulators at its

Nifty Pharma has immediate support placed at 10150 levels - GEPL

NIFTY PHARMA   Current Close: 10438.10    Trend : Negative


* NIFTY PHARMA is one of the perennially underperforming sectoral indices, as it closed down by around 1.11% at 10438.10, as against an up move of 0.60% in benchmark NIFTY 50.

* The Sector had made a recent swing high @ 11215.45 i

13/02/2017 5:03:19 PM | Posted in Broking Firm Views - Sector Report read full news
Revisiting FTAs to protect local pharma, med devices sector

The government is reviewing and renegotiating existing free trade agreements (FTAs) India has signed with different countries to protect the domestic pharma and medical devices sector, Union Minister Ananth Kumar said as per the PTI report. He also said that most of the anomalies in inverted duty structure both in pharma and medical devices sector have been rectified.

"We are sen

Aurobindo plans second U.S. plant as Trump calls for local production

MUMBAI - Indian drugmaker Aurobindo Pharma plans to set up a factory in the United States for injectable products, it said on Friday, days after U.S. President Donald Trump called on pharmaceutical companies to make more drugs locally.

Trump urged U.S. drug industry executives at a meeting last month to increase local manufacturing and to bring down medicine prices. H

Alkem Laboratories Q3 cons net up 25% at Rs 233.40 cr

Drug maker Alkem Laboratories has reported a growth of 24.9 per cent in its consolidated net profit at Rs 233.40 crore for the October-December quarter of 2016, helped by healthy growth in key markets of India and US amidst tough business environment.

The pharmaceutical company had posted the consolidated net profit of Rs 186.90 crore in the corresponding quarter of previous fiscal, s

Ipca Lab Q3 net surges 57% at Rs 41.38 cr

Ipca Laboratories has reported a growth of 57.21 per cent in its net profit at Rs 41.38 crore for the October-December quarter of 2016. The pharmaceutical company had posted the net profit of Rs 26.32 crore in the corresponding quarter of previous fiscal, said Ipca Laboratories in a filing to BSE on Friday.

The total revenue of company rose by 8.22 per cent to Rs 756.66 crore in Q3 FY

Buy Lupin Ltd For Target Rs.Rs1,702.00 - Karvy

Lupin would announce its results today.

*   We expect domestic growth for Lupin will be at 15% YoY . US would grow by 47 % to Rs 20.6 bn.

*   Japan to grow by 18 % to Rs 4.4 bn

*   Margins expected to be higher by 50 bps yoy mainly due to better gross margins and lower exps

*   We expect profits to

10/02/2017 12:26:35 PM | Posted in Broking Firm Views - Long Term Report read full news
Aurobindo Pharma falls over 3% on bourses

Shares of Aurobindo Pharma dipped over 3 per cent on the Bombay Stock Exchange amid profit booking after the company said that it has acquired four cell culture derived biosimilar products from TL Biopharmaceutical AG.

Weighed down by profit booking, shares of company declined as much as 3.59 per cent in intra-day trade to Rs 681.00 apiece on the Bombay Stock Exchange. In a similar fa